Skip To Main Content
Marilia Barros on Muck Rack

Marilia Barros

As seen in: Veja, Applied Animal Behaviour Science, BioRxiv, Bioprocess Online, Outsourced Pharma, Cell & Gene
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Marilia

Contact Marilia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

10.22.24 -- The Latest Strategies For Quantifying AAV Capsid Titer

|
By Marilia Barros, Amber Sherrick, Derek Pendlebury, Josh Russell Verified
| Cell & Gene Verified
Webinar: Revolutionizing Cell Therapy Manufacturing With AI: Precision, Efficiency, And Beyond The webinar will explore how AI is transforming cell therapy manufacturing by optimizing processes, enabling real-time monitoring, and enhancing quality control. It will cover AI applications in process development, improving efficiency, and personalizing treatments.
Open in Who Shared Issue with article?

The Latest Strategies For Quantifying AAV Capsid Titer

|
By Marilia Barros, Louis Garguilo Verified
| Outsourced Pharma
By Marilia Barros, Ph.D., Regeneron The assessment and monitoring of critical quality attributes (CQAs) are fundamental in the development of adeno-associated virus (AAV)-based gene therapies, as these attributes are closely linked to product quality, safety, and efficacy. Accurate quantification of capsid titers is essential for determining appropriate dosing regimens, as the total capsid count impacts both the efficacy and safety of the therapy.
Open in Who Shared Issue with article?

The Latest Strategies For Quantifying AAV Capsid Titer Original

|
By Marilia Barros
| Cell & Gene Verified
By Marilia Barros, Ph.D., Regeneron The assessment and monitoring of critical quality attributes (CQAs) are fundamental in the development of adeno-associated virus (AAV)-based gene therapies, as these attributes are closely linked to product quality, safety, and efficacy. Accurate quantification of capsid titers is essential for determining appropriate dosing regimens, as the total capsid count impacts both the efficacy and safety of the therapy.
Open in Who Shared View Duplicates (2) Issue with article?
See all 7 articles